Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393190 | 0.87 | CTSK (0.46) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12393191 | 0.82 | CTSK (0.44) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16508865 | 0.81 | FAAH (0.43) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14464620 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12228047 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2579949 | 0.79 | CTSK (0.44) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15216070 | 0.79 | FAAH (0.47) | CTSK | |
| SCHEMBL1774458 | 0.79 | CTSK (0.42) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24442329 | 0.76 | CTSK (0.46) | CTSKCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL11924539 | 0.76 | CTSK (0.50) | CTSKCHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-8609644-B2 | Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-12-17 | — | — | US | disclosed |
| EP-2004668-B1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA TAU IND FARMACEUTI (IT) | 2013-03-13 | — | — | EP | disclosed |
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | PKD1, ATP1A2, ATP1A1 | CTSK 1560/4885CHRM2 4202/4885CHRM4 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.